Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

A Case of Dilated Cardiomyopathy with Massive Left Ventricular Thrombus after Use of a Sibutramine-Containing Slimming Product

  • Heo, Seung Hye (Division of Cardiology, Department of Medicine, Seoul Paik Hospital, Inje University School of Medicine) ;
  • Kang, Min-Ho (Division of Cardiology, Department of Medicine, Seoul Paik Hospital, Inje University School of Medicine)
  • Published : 2013.09.30
⟨ Previous Next ⟩

Abstract

Sibutramine, which acts as an anti-obesity drug by inhibiting reuptake of serotonin and norepinephrine, has now been banned due to cardiovascular adverse effects. However, despite being banned, it is not uncommon for people to purchase products with sibutramine or its analogues used as adulterants in non-prescription slimming products or health foods available on the internet. Sibutramine has been associated with rare but serious adverse reactions such as cardiac arrhythmia including QT interval prolongation, myocardial infarction, and cardiomyopathy, as well as increases in blood pressure and pulse rate. Here, we report a case of a 32-year-old male who presented with dilated cardiomyopathy with massive left ventricular thrombus after taking unauthorized sibutramine-containing slimming pills sold over the internet.

Keywords

References

  1. Yuen YP, Lai CK, Poon WT, Ng SW, Chan AY, Mak TW. Adulteration of over-the-counter slimming products with pharmaceutical analogue--an emerging threat. Hong Kong Med J 2007;13:216-20.
  2. Tang MH, Chen SP, Ng SW, Chan AY, Mak TW. Case series on a diversity of illicit weight-reducing agents: from the well known to the unexpected. Br J Clin Pharmacol 2011;71:250-3. https://doi.org/10.1111/j.1365-2125.2010.03822.x
  3. Astrup A, Hansen DL, Lundsgaard C, Toubro S. Sibutramine and energy balance. Int J Obes Relat Metab Disord 1998;22 Suppl 1:S30-5; discussion S36-7, S42.
  4. von Haehling S, Lainscak M, Anker SD. Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon? Eur Heart J 2007;28:2830-1. https://doi.org/10.1093/eurheartj/ehm493
  5. Scheen AJ. Sibutramine on cardiovascular outcome. Diabetes Care 2011;34 Suppl 2:S114-9. https://doi.org/10.2337/dc11-s205
  6. Yim KM, Ng HW, Chan CK, Yip G, Lau FL. Sibutramine-induced acute myocardial infarction in a young lady. Clin Toxicol (Phila) 2008;46:877-9. https://doi.org/10.1080/15563650802136258
  7. Eroglu E, Gemici G, Bayrak F, Kalkan AK, Degertekin M. Acute myocardial infarction in a 24 year-old man possibly associated with sibutramine use. Int J Cardiol 2009;137:e43-5. https://doi.org/10.1016/j.ijcard.2008.06.017
  8. Gomez-Barrado JJ, Turegano S, Garciperez de Vargas FJ, Porras Y. Acute coronary syndrome in a young woman treated with sibutramine. Rev Esp Cardiol 2010;63:243.
  9. Harrison-Woolrych M, Clark DW, Hill GR, Rees MI, Skinner JR. QT interval prolongation associated with sibutramine treatment. Br J Clin Pharmacol 2006;61:464-9. https://doi.org/10.1111/j.1365-2125.2006.02574.x
  10. Ernest D, Gershenzon A, Corallo CE, Nagappan R. Sibutramine-associated QT interval prolongation and cardiac arrest. Ann Pharmacother 2008;42:1514-7. https://doi.org/10.1345/aph.1L129
  11. Poss J, Bohm M, Link A. [32-year-old patient with acute myocardial infarction possibly induced by the appetite suppressant sibutramine]. Dtsch Med Wochenschr 2010;135:965-8. https://doi.org/10.1055/s-0030-1253684
  12. Fernandez WG, Biswas AK. Myocardial infarction associated with sibutramine use: case report and discussion. Mil Med 2010;175:622-4. https://doi.org/10.7205/MILMED-D-10-00011
  13. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363:905-17. https://doi.org/10.1056/NEJMoa1003114
  14. Williams G. Withdrawal of sibutramine in Europe. BMJ 2010;340:c824. https://doi.org/10.1136/bmj.c824
  15. Cheung BM. Drug treatment for obesity in the post-sibutramine era. Drug Saf 2011;34:641-50. https://doi.org/10.2165/11592040-000000000-00000
  16. Colman E. Food and Drug Administration's Obesity Drug Guidance Document: a short history. Circulation 2012;125:2156-64. https://doi.org/10.1161/CIRCULATIONAHA.111.028381
  17. Muller D, Weinmann W, Hermanns-Clausen M. Chinese slimming capsules containing sibutramine sold over the Internet: a case series. Dtsch Arztebl Int 2009;106:218-22.
  18. Sayin T, Guldal M. Sibutramine: possible cause of a reversible cardiomyopathy. Int J Cardiol 2005;99:481-2. https://doi.org/10.1016/j.ijcard.2003.11.060

Cited by

  1. Sibutramine : Dilated cardiomyopathy with left ventricular thrombus: case report vol.1482, pp.1, 2013, https://doi.org/10.1007/s40278-013-7811-2
  2. Cardiovascular Safety Pharmacology of Sibutramine vol.23, pp.4, 2015, https://doi.org/10.4062/biomolther.2015.033
  3. Pharmacotherapy of Obesity: Limits and Perspectives vol.19, pp.4, 2013, https://doi.org/10.1007/s40256-019-00328-6
  4. Impact of timing of the anorexigen sibutramine administration on reproductive end‐points of male rats vol.127, pp.6, 2013, https://doi.org/10.1111/bcpt.13467